Table 2.
Summary of demographics of both study populations as well as the baseline characteristics for the glycaemic control parameters as measured after the 2-week placebo run-in period
| T2DM patients | Healthy volunteers | |||
|---|---|---|---|---|
| Parameter | Male | Female | Male | Female |
| Gender (n) | 9 | 9 | 8 | 8 |
| Age (years) | 56.8 (10.53) | 54.0 (8.56) | 22.1 (4.79) | 24.4 (7.25) |
| Body mass index (kg m−2) | 28.8 (2.39) | 32.7 (4.61) | 24.0 (4.07) | 24.6 (5.07) |
| Waist–hip ratio | 1.01 (0.047) | 0.92 (0.056) | 0.85 (0.061) | 0.77 (0.072) |
| Disease duration (years) | 5 (2.1) | 2 (1.6) | NA | NA |
| Prior treatment (n) | ||||
| No medication | 0 | 0 | 8 | 8 |
| OAD monotherapy | 7 | 5 | 0 | 0 |
| OAD combination | 2 | 4 | 0 | 0 |
| Statin | 3 | 3 | 0 | 0 |
| Antihypertensive | 3 | 2 | 0 | 0 |
| Glucose (mmol l−1) | 11.8 (3.09) | 11.2 (4.96) | 4.7 (0.31) | 4.6 (0.63) |
| HBA1c percentage (%) | 7.3 (0.84) | 6.9 (1.74) | 4.6 (0.32) | 4.7 (0.27) |
| Insulin (mU l−1) | 11.7 (3.00) | 12.6 (6.67) | 10.4 (8.03) | 9.8 (4.89) |
| C-peptide (nmol l−1) | 1.1 (0.25) | 1.0 (0.37) | 0.6 (0.33) | 0.8 (0.38) |
The data in parentheses represent the SD. OAD, oral antidiabetic drug.